Who
Jay R. Luly
President and CEO
Company insider
Files Form 4 as: President and CEO, Enanta Pharmaceuticals.
In numbers
- Trades disclosed
- 137
- Buys
- 1
- Sells
- 19
- Bought
- $256K
- Sold
- $14.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Dec 2013
- Last trade
- 12 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $88K6,155 at $14.25 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $88K6,155 at $14.25 | filing |
| 5 Dec 2025filed 5 Dec 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $67K4,743 at $14.23 | filing |
| 1 Dec 2025filed 3 Dec 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $27K1,885 at $14.12 | filing |
| 25 Nov 2025filed 26 Nov 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —310,000 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $42K7,484 at $5.59 | filing |
| 12 Feb 2025filed 12 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $256K45,000 at $5.69 | filing |
| 6 Dec 2024filed 10 Dec 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K5,142 at $8.06 | filing |
| 1 Dec 2024filed 3 Dec 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $33K3,829 at $8.60 | filing |
| 27 Nov 2024filed 27 Nov 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,400 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K1,584 at $12.41 | filing |
| 5 Dec 2023filed 6 Dec 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $70K7,230 at $9.63 | filing |
| 1 Dec 2023filed 5 Dec 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $55K5,787 at $9.49 | filing |
| 22 Nov 2023filed 22 Nov 2023 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —264,000 at $0.00 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Jay R. Luly; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.